Suplementação de resveratrol como prevenção das doenças cardiovasculares: uma revisão de literatura

Abstract

Introduction: Cardiovascular disease is among the leading causes of death worldwide, including conditions such as hypertension, atherosclerosis, myocardial infarction, and stroke. Resveratrol, a polyphenol found in grapes and red wine, has been studied for its potential to reduce risk factors and help prevent cardiovascular disease. Objective: Evaluate the effect of resveratrol in the prevention of cardiovascular disease. Methods: Randomized clinical trials published in the last ten years were selected from the PubMed database. These studies investigated the effects of resveratrol supplementation on biochemical markers related to cardiovascular disease and included adult and elderly participants. Results: Nine randomized clinical trials were included, with intervention durations ranging from 6 to 26 weeks. Resveratrol doses varied between 100 and 1,000 mg/day. Various positive effects were found in different studies using varied dosages and methodologies, such as reduction in systolic and diastolic blood pressure, decreased arterial stiffness, increased HDL-c, reduced LDL-c and oxidized LDL, and lower inflammatory markers (C- reactive protein and IL-6). However, adverse effects were also reported—mostly mild, such as diarrhea, dizziness, and polyuria—and one study identified an increase in cardiovascular risk markers. Conclusion: Resveratrol showed improvements in several cardiovascular risk markers; however, due to the heterogeneity of protocols and dosages, it is still not possible to establish safe clinical recommendations.